Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 14.13 billion. The enterprise value is 1.10 billion.
Important Dates
The last earnings date was Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 66.84 million shares outstanding. The number of shares has decreased by -1.14% in one year.
| Current Share Class | 66.84M |
| Shares Outstanding | 66.84M |
| Shares Change (YoY) | -1.14% |
| Shares Change (QoQ) | -3.43% |
| Owned by Insiders (%) | 0.26% |
| Owned by Institutions (%) | 27.22% |
| Float | 57.03M |
Valuation Ratios
The trailing PE ratio is 4.83.
| PE Ratio | 4.83 |
| Forward PE | n/a |
| PS Ratio | 3.09 |
| PB Ratio | 0.82 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | 0.39 |
| EV / Sales | 0.26 |
| EV / EBITDA | 0.43 |
| EV / EBIT | 0.44 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.50, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.50 |
| Quick Ratio | 10.36 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | n/a |
| Interest Coverage | 93.40 |
Financial Efficiency
Return on equity (ROE) is 19.07% and return on invested capital (ROIC) is 64.14%.
| Return on Equity (ROE) | 19.07% |
| Return on Assets (ROA) | 9.36% |
| Return on Invested Capital (ROIC) | 64.14% |
| Return on Capital Employed (ROCE) | 15.31% |
| Weighted Average Cost of Capital (WACC) | 6.78% |
| Revenue Per Employee | 7.60M |
| Profits Per Employee | 5.11M |
| Employee Count | 605 |
| Asset Turnover | 0.25 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Zealand Pharma has paid 113.06 million in taxes.
| Income Tax | 113.06M |
| Effective Tax Rate | 3.53% |
Stock Price Statistics
The stock price has decreased by -58.63% in the last 52 weeks. The beta is 0.47, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -58.63% |
| 50-Day Moving Average | 245.78 |
| 200-Day Moving Average | 295.85 |
| Relative Strength Index (RSI) | 29.89 |
| Average Volume (20 Days) | 397,750 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 4.60 billion and earned 3.09 billion in profits. Earnings per share was 43.77.
| Revenue | 4.60B |
| Gross Profit | 4.60B |
| Operating Income | 2.71B |
| Pretax Income | 3.20B |
| Net Income | 3.09B |
| EBITDA | 2.74B |
| EBIT | 2.71B |
| Earnings Per Share (EPS) | 43.77 |
Full Income Statement Balance Sheet
The company has 13.51 billion in cash and 484.00 million in debt, with a net cash position of 13.03 billion or 194.88 per share.
| Cash & Cash Equivalents | 13.51B |
| Total Debt | 484.00M |
| Net Cash | 13.03B |
| Net Cash Per Share | 194.88 |
| Equity (Book Value) | 17.24B |
| Book Value Per Share | 257.88 |
| Working Capital | 16.26B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -1.48 billion and capital expenditures -51.37 million, giving a free cash flow of -1.53 billion.
| Operating Cash Flow | -1.48B |
| Capital Expenditures | -51.37M |
| Depreciation & Amortization | 20.95M |
| Net Borrowing | -31.16M |
| Free Cash Flow | -1.53B |
| FCF Per Share | -22.94 |
Full Cash Flow Statement Margins
Gross margin is 100.00%, with operating and profit margins of 59.03% and 67.21%.
| Gross Margin | 100.00% |
| Operating Margin | 59.03% |
| Pretax Margin | 69.66% |
| Profit Margin | 67.21% |
| EBITDA Margin | 59.49% |
| EBIT Margin | 59.03% |
| FCF Margin | n/a |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.14% |
| Shareholder Yield | 1.14% |
| Earnings Yield | 20.71% |
| FCF Yield | -10.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Analyst Forecast
The average price target for Zealand Pharma is 383.58, which is 81.45% higher than the current price. The consensus rating is "Buy".
| Price Target | 383.58 |
| Price Target Difference | 81.45% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | -42.16% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zealand Pharma has an Altman Z-Score of 8.84 and a Piotroski F-Score of 3.
| Altman Z-Score | 8.84 |
| Piotroski F-Score | 3 |